Human ECs have a transcription profile similar to human embryonic stem cells (hESCs) and have been used as a model of early human development[@R9]. Previous studies demonstrated that human L1s are expressed in ECs and hESCs[@R3],[@R10]. We confirmed these findings by conducting L1 expression analyses in male (N-Tera2D1, 833KE, and 2102Ep) ECs, and a female (PA-1) EC-derived cell line that exhibits a restricted ectodermal differentiation pattern ([Figure 1a](#F1){ref-type="fig"}; [Supplemental Figures 1](#SD1){ref-type="supplementary-material"}, [2a & 2c](#SD2){ref-type="supplementary-material"}).

We next assayed a human L1 element (*LRE3*)[@R11] tagged with different indicator cassettes (*mneoI*, *mneoI/ColE1* or *mEGFPI*)[@R12],[@R13],[@R14] for retrotransposition ([Supplemental Figure 3](#SD3){ref-type="supplementary-material"}). An inactive L1 (pJM111/L1~RP~*mEGFPI*)[@R13],[@R14] served as a negative control. *LRE3* retrotransposition was readily detected in HeLa cells, but not ECs ([Figure 1b](#F1){ref-type="fig"}; [Supplemental Figures 2b](#SD2){ref-type="supplementary-material"} & [3](#SD3){ref-type="supplementary-material"}). Since these assays rely on reporter gene expression to detect retrotransposition, the above data suggest that L1 retrotransposition is inhibited in ECs. Alternatively, as observed in some experiments with neural progenitor cells (NPCs)[@R5],[@R8], the indicator cassette delivered by L1 retrotransposition may be silenced in ECs. Thus, we isolated genomic DNA from HeLa and PA-1 cells that were transfected either with pLRE3/*mEGFPI* or pJM111/L1~RP~*mEGFPI* seven days post-transfection[@R12],[@R13],[@R14]. PCR revealed the unspliced (vector) and spliced (retrotransposition) products in pLRE3/*mEGFPI* transfected HeLa cells, but only the unspliced product in pJM111/L1~RP~*mEGFPI* transfected HeLa cells ([Figure 1c](#F1){ref-type="fig"} and [Supplemental Figure 3](#SD3){ref-type="supplementary-material"}). Notably, we also observed the spliced product in pLRE3/*mEGFPI* transfected PA-1 cells ([Figure 1c](#F1){ref-type="fig"}), suggesting that the retrotransposed *EGFP* reporter gene (herein referred to as *L1-retro-EGFP*) was not expressed from the PA-1 genome.

To dissect the mechanism of *L1-retro-EGFP* silencing, we transfected cells with pLRE3/*mEGFPI.* Seven days later, cells were treated with the IHDAC trichostatin A (TSA) for 14 hours ([Figure 2a](#F2){ref-type="fig"})[@R5],[@R8]. Flow cytometry revealed a modest increase in the number of EGFP-positive cells after TSA treatment of HeLa cells (1.3% *vs.* 2.6%; [Figure 2a](#F2){ref-type="fig"}). In contrast, we observed a marked increase of *L1-retro-EGFP* expression after TSA treatment of PA-1 and 2102Ep cells (\~22-fold and \~12-fold, respectively; [Figure 2a](#F2){ref-type="fig"}). A similar response also was observed in 833KE cells; however, we did not detect retrotransposition in N-Tera2D1 cells ([Supplemental Figure 4a & b](#SD4){ref-type="supplementary-material"}, data not shown). Reactivation of *L1-retro-EGFP* expression also was seen upon treatment of PA-1 cells with sodium butyrate and valproic acid, but not upon treatment with 5-azacytidine ([Supplemental Figure 4c](#SD4){ref-type="supplementary-material"}). Controls revealed that TSA treatment reactivated existing *L1-retro-EGFP* events and did not result in a burst of L1 retrotransposition ([Supplemental Figure 4d-f](#SD4){ref-type="supplementary-material"}). Thus, several ECs accommodate L1 retrotransposition, but the resultant *L1-retro-EGFP* events undergo efficient silencing.

Efficient silencing in PA-1 cells also was observed when the cytomegalovirus immediate early (CMV) promoter driving *EGFP* expression was replaced with the mouse phosphoglycerate kinase 1 (*pgk*) promoter or when the SV40 polyadenylation signal was removed from the L1 expression construct ([Supplemental Table 1](#SD11){ref-type="supplementary-material"})[@R13],[@R14]. Similarly, we observed efficient *L1-retro-EGFP* silencing when the cassette was delivered by a mouse L1 (T~GF~21)[@R15], a synthetic mouse L1 (L1SM)[@R16], or a zebrafish LINE-2 element that retrotransposes at a low level in human cells[@R17]. In each instance, TSA treatment reactivated the silenced *L1-retro-EGFP* cassette ([Supplemental Table 1](#SD11){ref-type="supplementary-material"}, [Supplemental Figures 4h & i](#SD4){ref-type="supplementary-material"}, and data not shown). Thus, the establishment of *L1-retro-EGFP* silencing appears to be independent of viral sequences or sequences within the engineered LINE constructs.

Retroviral insertions also can be efficiently silenced in ECs[@R18],[@R19],[@R20],[@R21]. To determine if the kinetics of retroviral and *L1-retro-EGFP* silencing are similar, we infected PA-1 cells with an HIV virus (HIV89.6ΔENV) or a replication-deficient MMLV retrovirus carrying an *EGFP* reporter gene. The cells then were treated with or without TSA seven days post-infection. Flow cytometry revealed that TSA treatment modestly increased the number of EGFP-positive PA-1 cells in the retroviral-based experiments, though the extent of reactivation was not as pronounced as in the *L1-retro-EGFP* experiments (\~2-fold in the HIV experiment or \~3-fold in the MMLV experiment *vs.* \> 20-fold in the L1 experiments; [Figure 2b](#F2){ref-type="fig"} and [Supplemental Table 1](#SD11){ref-type="supplementary-material"}). Controls demonstrated that transfection of PA-1 or 2102Ep cells with a linearized neomycin or hygromycin expression plasmid readily led to the formation of drug resistant foci ([Supplemental Figure 4g](#SD4){ref-type="supplementary-material"} and data not shown). Thus, the efficiency of *EGFP* reporter gene silencing appears to depend on the mechanism of integration.

We next characterized thirty-six clonal PA-1 cell lines containing at least one silenced *L1-retro-EGFP* event (see [Supplemental Methods](#SD11){ref-type="supplementary-material"}). Thirty-three cell lines exhibited efficient silencing and EGFP-positive cells were detected only upon TSA treatment (*e.g.*, pk-5; [Figure 3a](#F3){ref-type="fig"}). Three cell lines (*e.g.,* pk-87; [Supplemental Figure 5](#SD5){ref-type="supplementary-material"}) exhibited only modest *L1-retro-EGFP* silencing, though TSA treatment increased the number of EGFP-positive cells ([Supplementary Figure 5](#SD5){ref-type="supplementary-material"}). Characterization of nine retrotransposition events revealed that six occurred either within known genes or in genomic regions associated with expressed sequence tags ([Supplemental Table 2](#SD11){ref-type="supplementary-material"}), which is consistent with previous studies in cultured cells[@R3],[@R5],[@R8],[@R12],[@R13].

The pk-5 clonal cell line was analyzed in greater detail. Southern blot and inverse PCR[@R3] analyses revealed the presence of a single full-length *L1-retro-EGFP* event on chromosome 12q21.1 ([Figures 3a & 3b](#F3){ref-type="fig"}; [Supplemental Figure 6a](#SD6){ref-type="supplementary-material"}). Treating pk-5 cells with TSA ([Figure 3a](#F3){ref-type="fig"}; [Supplemental Movie](#SD11){ref-type="supplementary-material"}), sodium butyrate, or valproic acid ([Supplemental Figure 6b](#SD6){ref-type="supplementary-material"}, see 24 hour panels; data not shown) reactivated the silenced *L1-retro-EGFP* event. Additional experiments revealed that *L1-retro-EGFP* reactivation did not require cell division ([Supplemental Figure 7](#SD7){ref-type="supplementary-material"}), and that withdrawal of histone deacetylase inhibitors led to a steady decrease in the number of EGFP-positive cells over a 120 hour period ([Figure 3c](#F3){ref-type="fig"}; [Supplemental Figure 6b](#SD6){ref-type="supplementary-material"}). Thus, the maintenance of *L1-retro-EGFP* silencing requires the presence of active HDACs. The slower kinetics required to reestablish the silenced state in pk-5 cells may reflect the half-life of the EGFP protein (\~20 hours)[@R22].

To test if reactivation of *L1-retro-EGFP* expression is correlated with histone modifications at the L1 integration site, we performed ChIP on naïve and TSA-treated pk-5 cells using antibodies diagnostic for transcriptionally active (acetylated histone-H4 (AcH4)) and transcriptionally repressed (dimethyl histone-H3-Lys9 (diMeH3)) chromatin[@R23]. Quantitative-PCR experiments revealed a \~9-fold increase in the amount of *EGFP* sequences precipitated using the AcH4 antibody in TSA treated pk-5 cells when compared to the untreated cell line, and an \~7-fold decrease in the amount precipitated using the diMeH3 antibody in TSA treated pk-5 cells when compared to the untreated cell line ([Figure 3d](#F3){ref-type="fig"}). Thus, reactivation of *L1-retro-EGFP* expression is accompanied by histone modifications, suggesting that silencing principally is mediated at the chromatin level.

Previous studies indicated that the silencing of retroviral sequences is attenuated in differentiating cells[@R19],[@R20],[@R21]. To test if differentiation affects *L1-retro-EGFP* silencing, PA-1 cells were transfected with pLRE3/*mEGFPI.* Cells were grown for seven days in standard medium (10% fetal bovine calf serum (FBS)) or medium that promotes differentiation (DM; see [Supplemental Methods](#SD11){ref-type="supplementary-material"}) and then were treated with or without TSA to assay for *L1-retro-EGFP* silencing. TSA-treatment resulted in similar numbers of EGFP-positive cells when cells were grown in 10% FBS or DM, indicating that the growth medium did not dramatically affect L1 retrotransposition ([Figure 4a](#F4){ref-type="fig"}; [Supplemental Figures 8a & 8b](#SD8){ref-type="supplementary-material"}). However, we readily detected EGFP-positive cells in DM without TSA treatment (\~10% of cells grown in DM *vs.* \<0.3% of cells grown in 10% FBS; [Figure 4a](#F4){ref-type="fig"}; [Supplemental Figures 8a & 8b](#SD8){ref-type="supplementary-material"}). Controls verified that the majority of EGFP-positive PA-1 cells identified in DM medium stained negatively for Oct4 and positively for the epithelial cell surface marker Lu5 ([Supplemental Figures 8c-e](#SD8){ref-type="supplementary-material"}). Similar results were obtained from experiments using either a human L1 (pJM101/LRE3)[@R3] or a codon-optimized mouse L1 (pCEPL1SM)[@R16] containing the *mneoI* retrotransposition indicator cassette ([Supplemental Figures 3](#SD3){ref-type="supplementary-material"} & [8f](#SD8){ref-type="supplementary-material"}). Thus, *L1-retro-reporter* gene silencing is more efficient in ECs when compared to differentiating cells. Consistently, 2102Ep cells, which do not differentiate when grown in DM[@R24], exhibited *L1-retro-EGFP* silencing when experiments were conducted in either 10% FBS or DM ([Supplemental Figure 9](#SD9){ref-type="supplementary-material"}).

We next generated a population of silenced *L1-retro-EGFP* retrotransposition events in PA-1 cells ([Figure 4b](#F4){ref-type="fig"}). The EGFP-negative cells were grown in 10% FBS or DM for seven days in the presence of the reverse transcriptase inhibitor 3′-azido-3′-deoxythymidine (AZT) to repress further L1 retrotransposition[@R25]. Notably, TSA treatment was required to reactivate *L1-retro-EGFP* expression in both 10% FBS and DM ([Figure 4b](#F4){ref-type="fig"}). Consistently, growing the clonal pk-5 cell line in DM rarely led to EGFP-positive cells (\~2% of cells; [Supplemental Figure 10](#SD10){ref-type="supplementary-material"}). Thus, differentiation is not sufficient to reactivate previously silenced *L1-retro-EGFP* insertions.

Our study builds on existing literature, suggesting that host mechanisms act to regulate L1 retrotransposition[@R5],[@R26],[@R27],[@R28],[@R29],[@R30]. We propose that *L1-retro-EGFP* silencing occurs by a two-step process ([Figure 4c](#F4){ref-type="fig"}). First, since reporter cassettes delivered by various non-LTR retrotransposons are silenced in PA-1 cells, we speculate that nascent L1 cDNAs may be targeted by host factors in an apparently sequence-independent manner to 'initiate' *L1-retro-EGFP* silencing either during target-site primed reverse transcription or immediately after integration. Second, since the removal of IHDACs results in the re-establishment of *L1-retro-EGFP* silencing, we propose that histone modification enzymes (deacetylases) act to maintain silencing, and that silencing in ECs, at least in the short term, does not require methylation of the retrotransposed *L1-retro-EGFP* cDNA. It remains possible that L1s insert into chromosomal regions that are preferentially silenced in ECs when compared to differentiated cells, though such a result lacks precedence and is not supported by the initial characterization of retrotransposition events in PA-1 cells ([Supplemental Table 2](#SD11){ref-type="supplementary-material"}). The silencing of *L1-retro-EGFP* events in ECs that express endogenous L1s may seem paradoxical. However, since 3/36 (\~8%) *L1-retro-EGFP* events in PA-1 cells evaded complete silencing (see [Supplemental Figure 5](#SD5){ref-type="supplementary-material"}), we suggest that some full-length endogenous L1s are expressed from favorable genomic contexts, and speculate that L1-mediated reporter gene silencing may represent a mechanism to regulate retrotransposition in cells that naturally express human L1s.

We further determined that *L1-retro-EGFP* silencing is attenuated in differentiating cells, but that differentiation is not sufficient to reactivate a previously silenced *L1-retro-EGFP* cassette. A similar scenario has been reported for retroviral silencing in pluripotent cells[@R19],[@R20],[@R21]. Thus, we speculate that host factor(s) required for the initiation of *L1-retro-EGFP* silencing are expressed in multipotent ECs and undergo down-regulation during cellular differentiation. Alternatively, a repressor of *L1-retro-EGFP* silencing could be activated upon differentiation. In either case, we have uncovered a novel mechanism that mediates the silencing of engineered L1 retrotransposition events in ECs.

METHODS SUMMARY (detailed protocols are available in [Supplemental Methods](#SD11){ref-type="supplementary-material"}) {#S1}
======================================================================================================================

Cell culture and plasmid DNA {#S2}
----------------------------

HeLa and human ECs were grown as described previously[@R3]. DNA constructs are described in the [Supplemental Methods](#SD11){ref-type="supplementary-material"} section (see also [Supplemental Methods](#SD11){ref-type="supplementary-material"} for specific details and references to previously published works).

Retrotransposition assays {#S3}
-------------------------

Cell transfection and L1-retrotransposition assays were performed as described previously[@R12],[@R13],[@R14]. In some instances, puromycin was added to the medium to select for the episomal L1 expression vector. Where indicated, transfected cells were treated with 500nM-1μM Trichostatin A (TSA, Sigma), 1mM Valproic Acid (Vpa, Sigma), 1μM Sodium Butyrate (NaB, Sigma) for 14--16 hours or with 25μM 5-Azacytidine (5-Aza, Sigma) for at least 56 hours to assay for the reactivation of *L1-retro-EGFP* expression. Silencing assays previously were reported in refs. [@R5] and [@R8]. Notably, treating cells for longer than 24 hours with TSA resulted in toxicity; thus, we performed time course studies to optimize the TSA treatment time for our assays.

Southern blot and PCR {#S4}
---------------------

PCR reactions to follow the removal of the intron from the retrotransposition indicator cassette were conducted as described[@R13],[@R14]. Southern blot and inverse PCR were conducted as described previously[@R3],[@R5],[@R12].

Western-blot and Immunocytochemistry {#S5}
------------------------------------

Western-blot and immunocytochemistry analyses were performed as described previously[@R3].

Chromatin Immunoprecipitation assays (ChIP) {#S6}
-------------------------------------------

ChIP assays were performed as described previously[@R23].
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======================
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![L1 expression and retrotransposition in EC cells\
**(a)** ECs express endogenous L1 ORF1p. The ribosomal S6 protein is a loading control. MW=molecular weight standards. **(b)** Results of the retrotransposition assay in HeLa and EC cells. G418-resistant foci that expressed the retrotransposed *NEO* reporter gene were stained for visualization. **(c)** PCR assay for intron removal (retrotransposition) in both HeLa and PA-1 cells. LRE3=a retrotransposition-competent L1. JM111=a retrotransposition-defective L1. MW= 1 kb molecular weight ladder.](nihms210085f1){#F1}

![Engineered L1 retrotransposition events are efficiently silenced in EC cells\
**(a)** A cartoon of an L1 and the experimental rationale (top). Cells were transfected with an RC-L1 (kpLRE3/*mEGFPI*, top two panels; cpLRE3/*mEGFPI*, bottom panel) and were untreated (left panel) or treated with TSA (right panel). The percentage of EGFP-positive cells and standard deviation (n=3) is indicated. Hoechst staining (blue) highlights the nuclei of cells. P=experiments where puromycin was used to select for the episomal L1 expression plasmid. **(b)** Retroviral insertions are not efficiently silenced in PA-1 cells (see methods). The graphs indicate the percentage of EGFP-positive cells and the standard deviation (n=3).](nihms210085f2){#F2}

![Analyses of L1 silencing in a clonal (pk-5) cell line\
**(a)** The cartoon indicates the chromosomal location of a silenced *L1-retro-EGFP* event in a clonal PA-1 cell line. *L1-retro-EGFP* expression can be reactivated by TSA treatment. **(b)** Southern blot analysis reveals that pk-5 cells contain a single *L1-retro-EGFP* event. Genomic DNA was digested with *Hind*III and the blot was probed with an α-^32^P radiolabeled *EGFP* probe. MW=molecular weight standards (kb). **(c)** Withdrawal of TSA (bottom panels) results in the reestablishment of *L1-retro-EGFP* silencing. **(d)** ChIP analysis on naïve and TSA treated pk-5 cells using AcH4 and diMeH3 antibodies. qPCR revealed the enrichment (AcH4) or depletion (diMeH3) of the retrotransposed *EGFP* sequences in the TSA treated pk-5 cells. The input cycle threshold (Ct) was designated as 1 and used to calculate fold change differences. Samples were run in triplicate from the same experiment. The standard deviation (SD, n=3) is indicated in the graph.](nihms210085f3){#F3}

![Analysis of L1 silencing in differentiating cells\
**(a)** The cartoon shows the experimental rationale. Silencing was efficient in PA-1 cells grown in medium containing 10% FBS (white rectangles), but was attenuated in DM (gray rectangles). Red highlighted rectangles indicate experiments with TSA treatment. **(b)** Differentiation is not sufficient to derepress L1 silencing (details are provided in the text). In a & b, graphs indicate the percentage of EGFP-positive cells and the standard deviation (n=3). **(c)** A model for the initiation and maintenance of L1 silencing in EC cells (details are provided in the text).](nihms210085f4){#F4}
